Actos, the only other Type 2 diabetes drug within the same class as Avandia, has picked up where Avandia left off. Prior to Avandia's demise in the court of public and medical opinion, the GlaxoSmithKline drug had reached sales of $3 billion a year. Actos has since eclipsed that, amidst the belief that Actos was a safer alternative to the much-vilified Avandia.
GlaxoSmithKline maintains that Avandia, at its worst, is no worse than Actos.
It appears now that Actos, which has also been fingered for Actos heart failure and other adverse reactions stemming from the treatment of Actos diabetes, has potentially seen the chickens come home to roost. Actos, according to the Washington Drug Letter of February 7, has been the subject of FDA safety reviews in recent months.
Now it's been included on a watch list the FDA posted on its Web site on January 31.
Among the Actos side effects previously noted, including the relationship between Actos and heart failure and problems with Actos liver, is the newfound potentiality for bladder cancer risk.
But now there is yet another concern—that of rhabdomyolysis, which is characterized by the release of muscle fibers into the bloodstream, triggering damage to the kidney.
READ MORE ACTOS SIDE EFFECTS LEGAL NEWS
The FDA noted that its investigations into Actos side effects, as well as other drugs, were in the early stages, and inclusion on the active list "means that FDA has identified a potential safety issue, but does not mean that FDA has identified a causal relationship and the listed risk," according to an FDA statement.
Doctors began switching their patients to Actos (pioglitazone) following revelations of Avandia heart risk in 2007. Actos, which has also been linked to Actos CHF, is the only alternative besides Avandia in the class to which both drugs belong. With severe restrictions on Avandia, diabetes patients are hoping that Actos is truly the safer alternative—and that another shoe isn't about to drop.